SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

Feature selection process. We filtered probe sets based on performance in studies on technical and spatial reproducibility (i.e. intratumoral heterogeneity), association with ESR1 and PGR expression and association with proliferation. We applied additional filtering steps to reduce the signature to 18 robust probe set